Divergent TIR signaling domains in TLR7 and TLR9 control opposing effects on systemic autoimmunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40794441.
- Also identified by DOI 10.1172/JCI189566 and PMC identifier 12578402.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Toll like receptor (TLR) 7 and 9, endosomal sensors for RNA and DNA, are key mediators of autoreactivity. Although generally considered homologous, they paradoxically have opposing effects on lupus: TLR7 exacerbates the disease while TLR9 protects from it How they mediate opposing effects in autoimmunity remains undetermined. We hypothesized that differences in signaling qualities of the Toll-Interleukin 1 Receptor (TIR) domains of TLR7 and TLR9 could be responsible for their opposing effects. To test this, we introduced the TIR domain of TLR9 into the endogenous Tlr7 locus and the TLR7 TIR domain into the endogenous Tlr9 locus of mice, creating chimeric molecules termed TLR779 and TLR997. Lupus-prone MRL/lpr mice carrying Tlr779 had greatly ameliorated disease, while MRL/lpr mice carrying Tlr997 had markedly exacerbated disease compared with respective TlrWT mice. These experiments establish that TLR7 and TLR9 TIR domains have divergent properties and control disease quality, thus explaining the longstanding "TLR paradox".
Medical subject headings
- Toll-Like Receptor 7
- Toll-Like Receptor 9
- Signal Transduction
- Lupus Erythematosus, Systemic
- Autoimmunity
- Membrane Glycoproteins